| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 09/26/2002 | WO2001034119A9 Inhibitors of crystallization in a solid dispersion |
| 09/26/2002 | WO2001032156A3 Methods for treating fibroproliferative diseases |
| 09/26/2002 | WO2001023421A9 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 09/26/2002 | WO2001019977A9 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 09/26/2002 | WO2001019385A9 The use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses |
| 09/26/2002 | WO2001011054A9 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STAPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB) |
| 09/26/2002 | WO2000034495A3 A method of genetically modifying very primitive quiescent human hematopoietic stem cells |
| 09/26/2002 | US20020138857 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 09/26/2002 | US20020137932 Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma |
| 09/26/2002 | US20020137905 A membrane protein induced by interferons; treating and preventing cancer and viral infection; mediate trans-bilayer movement of membrane phospholipids |
| 09/26/2002 | US20020137892 An isolated peptide transmitter-like receptor polypeptide with specific amino acid sequence or variant which has immunomodulatory, neuromodulatory and endocrinomodulatory activity |
| 09/26/2002 | US20020137800 2-cyclopenten-1-one and its derivatives as inhibitors of the NF-kB factor |
| 09/26/2002 | US20020137798 Treatment of disorders secondary to organic impairments |
| 09/26/2002 | US20020137788 Coniosetin and derivatives thereof, process for the preparation and the use thereof |
| 09/26/2002 | US20020137778 Anticancer, antiarthritic, and antiinflammatory agents |
| 09/26/2002 | US20020137775 Novel delta dicarbonyl compounds and methods for using the same |
| 09/26/2002 | US20020137755 Tyrosine kinase inhibitors |
| 09/26/2002 | US20020137748 Reducing intestinal toxicity of a noncompetitive thymidylate synthase inhibitor by co-administering a folate derivative without blocking therapy; anticancer, antitumore agents |
| 09/26/2002 | US20020137741 Use as topical antibiotics |
| 09/26/2002 | US20020137733 Macrocyclic anti-viral compounds |
| 09/26/2002 | US20020137718 Nucleozymes |
| 09/26/2002 | US20020137716 Administering nucleotide sequence |
| 09/26/2002 | US20020137714 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 09/26/2002 | US20020137704 Aids therapy; administering enzyme inhibitor |
| 09/26/2002 | US20020137695 A nucleotide, e.g., 6-(beta-D-2-Deoxyribofuranosyl)-5-hydro-methyl-8H-pyrimido(4,5 -c)(1,2)pyridazin-7-one-5'-triphosphate, incorporated into a polynuceotide or an oligomucleotide; viricides; labels |
| 09/26/2002 | US20020137687 Novel compounds that inhibit tryptase activity |
| 09/26/2002 | US20020137686 Inhibitors of the ICE/ced-3 family of cysteine proteases |
| 09/26/2002 | US20020137202 Diagnosis, treatment, and prevention of disorders associated with a FCTRX nucleic acid, polypeptide, or an antibody specific for it |
| 09/26/2002 | US20020137156 Controlled dissolution crosslinked protein crystals |
| 09/26/2002 | US20020137155 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher Basidiomycetes mushroom |
| 09/26/2002 | US20020137050 Hybrid Dna sequence |
| 09/26/2002 | US20020137028 Use of neuronal apoptosis inhibitor protein (naip) |
| 09/26/2002 | US20020136819 Conserved concentrations of cocoa polyphenols by mixing carbohydrate or protein containing ingredients with a polyphenol conserving pretreatment ingredient and then with a cocoa polyphenol |
| 09/26/2002 | US20020136776 Poly( alpha -hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents |
| 09/26/2002 | US20020136741 Extracting with a polyoxyethylene detergent to deplete inner membranes, extracting remaining outer membranes with zwitterionic betaine dertergent to separate lipooligosaccharides from insoluble factions used for vaccines |
| 09/26/2002 | US20020136737 Isolated nucleic acids comprising Listeria dal and dat genes |
| 09/26/2002 | US20020136736 Or prophylactically or therapeutically effective fragment thereof in admixture with a pharmaceutically acceptable carrier |
| 09/26/2002 | US20020136735 Preparations that potentiate immunogenicity in low immunogenic antigens |
| 09/26/2002 | US20020136730 From coagulase-negative bacteria produced in substantially pure form; use of purified adhesin product as vaccine for production of antibodies effective against binding of homologous bacterial cells to polymeric materials |
| 09/26/2002 | US20020136720 Methods of using IMXP-888 and IMXP-888 antagonists |
| 09/26/2002 | US20020136703 Method for regulating IL-10 with IL-9, and applications thereof |
| 09/26/2002 | US20020136697 4-hydroxyisothiazole compounds |
| 09/26/2002 | DE10112771A1 New 3-acylamino-3-phenyl-propionic acid derivatives, are integrin inhibitors useful e.g. for treating thrombosis, cardiac infarction, angina pectoris, tumor diseases, inflammation, osteoporosis or infections |
| 09/26/2002 | CA2852293A1 Attenuated pasteurellaceae bacteria and an anti-bacterial vaccine prepared therefrom |
| 09/26/2002 | CA2469846A1 New interferon beta-like molecules |
| 09/26/2002 | CA2460779A1 Use of gram-negative bacterial membrane fraction for inducing the maturation of dendritic cells |
| 09/26/2002 | CA2441162A1 Pharmaceutical composition comprising, as an active ingredient, triazaspiro[5.5]undecane derivative |
| 09/26/2002 | CA2441155A1 Methods of treating respiratory conditions |
| 09/26/2002 | CA2441152A1 Hormone replacement therapy |
| 09/26/2002 | CA2441111A1 Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
| 09/26/2002 | CA2441095A1 Modified interferon beta with reduced immunogenicity |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2439757A1 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells |
| 09/26/2002 | CA2438942A1 Influenza vaccine formulations for intradermal delivery |
| 09/26/2002 | CA2438315A1 Attenuated pasteurellaceae bacteria and an anti-bacterial vaccine prepared therefrom |
| 09/26/2002 | CA2435847A1 Aniline derivatives useful as phosphodiesterase 4 inhibitors |
| 09/26/2002 | CA2404701A1 Triazole compounds having amide linkage |
| 09/25/2002 | EP1243655A1 Modified HPV E6 and E7 genes and proteins useful for vaccination |
| 09/25/2002 | EP1243276A1 Elongated and multiple spacers containing activatible prodrugs |
| 09/25/2002 | EP1243274A2 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 09/25/2002 | EP1243267A2 Amoxycillin and clavulanate containing pharmaceutical formulation |
| 09/25/2002 | EP1243264A2 Inhibition of nitric oxide production by retinoic acid |
| 09/25/2002 | EP1243259A1 Sustained release preparation comprising one or more antibiotics and polymers |
| 09/25/2002 | EP1243256A1 Vaccines absorbable by the transmucosal way |
| 09/25/2002 | EP1243255A2 Method of preparation of antibiotic compositions |
| 09/25/2002 | EP1242611A2 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 09/25/2002 | EP1242596A1 Methods and materials relating to novel von willebrand/thrombospondin-like polypeptides and polynucleotides |
| 09/25/2002 | EP1242592A2 A molecular switch for regulating mammalian gene expression |
| 09/25/2002 | EP1242590A2 Human lyases and associated proteins |
| 09/25/2002 | EP1242583A2 Human oxidoreductase proteins |
| 09/25/2002 | EP1242579A2 Th1 specific cd4 t cell lines and method for inducing them ex vivo |
| 09/25/2002 | EP1242455A1 N-alkylated peptides having antiangiogenic activity |
| 09/25/2002 | EP1242451A2 Compositions and methods for inhibiting endothelial cell proliferation |
| 09/25/2002 | EP1242449A1 Modified adenovirus fibre and uses |
| 09/25/2002 | EP1242447A1 Compounds and use thereof to modify transport across cell membranes |
| 09/25/2002 | EP1242441A2 Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef |
| 09/25/2002 | EP1242439A1 Method for preparing and isolating 9-deoxo-9(z)-hydroxyiminoerythromycin a |
| 09/25/2002 | EP1242438A1 Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| 09/25/2002 | EP1242437A2 Novel stromelysin inhibitors |
| 09/25/2002 | EP1242435A2 Medicaments for treatment of respiratory syncytial virus infections |
| 09/25/2002 | EP1242427A1 Novel piperidine and piperazine derivatives |
| 09/25/2002 | EP1242426A1 Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors |
| 09/25/2002 | EP1242417A1 Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
| 09/25/2002 | EP1242416A1 Substituted isoxazolines and their use as antibacterial agents |
| 09/25/2002 | EP1242415A1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242414A1 Pyrazolyl benzyl ethers |
| 09/25/2002 | EP1242413A1 Substituted 1,3,4-oxadiazoles and a method of reducing tnf-alpha levels |
| 09/25/2002 | EP1242410A1 Novel compounds |
| 09/25/2002 | EP1242407A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242406A1 Novel compounds |
| 09/25/2002 | EP1242400A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242395A1 Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent |
| 09/25/2002 | EP1242388A1 Method for production of a triazolinethione derivative |
| 09/25/2002 | EP1242382A1 Tricyclic protein kinase inhibitors |
| 09/25/2002 | EP1242371A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242365A1 Acyl pseudodipeptides which carry a functionalised auxiliary arm |
| 09/25/2002 | EP1242124A1 Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol |
| 09/25/2002 | EP1242122A2 Delivery of proteins across polar epithelial cell layers |
| 09/25/2002 | EP1242120A2 Combinations of growth factors and i:upa or i:mmp for the treatment of damaged tissue |
| 09/25/2002 | EP1242119A2 Combinations for the treatment of dna viral infections comprising a loop diuretic and a cardiac glycoside |